HER2 positive breast cancer and its treatment with trastuzumab, where are we now?
نویسندگان
چکیده
HER2-positive breast cancer is one of the most common types female around world. This review summarizes information and results HER2 -positive trials compares their with standards in Bosnia Herzegovina. It done based on a literature search PubMed Google Scholar. analyzed trastuzumab as golden treatment standard for treatments. Trastuzumab monoclonal anti-human epidermal growth factor receptor antibody besides its effect cancer, suggests within 1 year. Herzegovina have also accepted guidelines they are step latest achievements worldwide.
منابع مشابه
Reflection for the undergraduate on writing in the portfolio: where are we now and where are we going?
Introduction: The portfolio can be seen as a tool for assessmentof a variety of learning activities that differ in content, usage, andassessment. The portfolio not only meets the learner’s educationalneeds but also the political and public reassurance demand thatthe health professional has achieved the required competency ofthe curriculum that allows him or her to practice safely with orwithout...
متن کاملHER2-positive breast cancer: beyond trastuzumab.
The outlook for patients with HER2-positive breast cancer was revolutionized by the development of trastuzumab (Herceptin), a humanized murine monoclonal antibody. Use of this agent led to improved overall survival when it was added to chemotherapy for the treatment of metastatic breast cancer. Improved understanding of mechanisms of resistance to trastuzumab has facilitated the development of ...
متن کاملAdjuvant trastuzumab in HER2-positive breast cancer.
BACKGROUND Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab. METHODS We randomly assigned 3222 women with HER2-positive early-stage breast cancer to receive ...
متن کاملAdjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon, M.D., Ph.D., Wolfgang Eiermann, M.D., Nicholas Robert, M.D., Tadeusz Pienkowski, M.D., Miguel Martin, M.D., Michael Press, M.D., Ph.D., John Mackey, M.D., John Glaspy, M.D., Arlene Chan, M.D., Marek Pawlicki, M.D., Tamas Pinter, M.D., Vicente Valero, M.D., Mei-Ching Liu, M.D., Guido Sauter, M.D., Gunter von Minckwitz, M.D., Frances Visco, J.D., Valerie Bee, M.Sc., Marc Buyse, Sc....
متن کاملHepatitis C treatment: where are we now?
Chronic hepatitis C infection affects millions of people worldwide and confers significant morbidity and mortality. Effective treatment is needed to prevent disease progression and associated complications. Previous treatment options were limited to interferon and ribavirin (RBV) regimens, which gave low cure rates and were associated with unpleasant side effects. The era of direct-acting antiv...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Bioengineering studies
سال: 2022
ISSN: ['2744-1636']
DOI: https://doi.org/10.37868/bes.v3i2.id239